Genmab — April 2020

[gentogen]

= (DuoHexabody-CD37)

[E_L]

no, not yet, we were waiting for that one, IND was filed, You have the link pls?

[gentogen]

ClinicalTrials.gov

(clinicaltrials.gov)

[E_L]

thanks. will give Jan something to talk about next week

[peter12]

Lidt læsestof til pensionisten. Ved ikke om det har været linket før ?
https://ir.genmab.com/static-files/50feecc4-912d-4dea-be45-5336fb10788c

[peter12]

Vi afventer rapporten ...

[Bulder]

det var da den ringeste lukkeauktion nogensinde

[Helge_LarsenPI-redaktør]

Der var flere pharma aktier som faldt tilbage i eftermiddag.

[E_L]

yes, noted the same, seems like a bit of
rotation, pharma has admittedly done very well

[peter12]

Genmab har en ny fan https://twitter.com/VincentRK/status/1254810548996366337?s=20

[JKY_VH]

haha peter12 og god morgen:-) Håber at vi snart kan sige det samme om Novod.

[transalp]

Go morgen..

[bibob]

God morgen. :-).

[E_L]

Jeffrey Cohen, MD: The Success of Ofatumumab in Relapsing MS https://www.youtube.com/watch?v=3hz6GX3lUKk

[E_L]

Blood Cancer Journal: DuoHexaBody-CD37, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies https://www.nature.com/articles/s41408-020-0292-7

[E_L]

follows the new trial @gentogen posted yesterday

[E_L]

DuoHexaBody-CD37 not only outperformed all other CD37 antibody variants evaluated in ex vivo CDC assays using primary CLL patient samples, but also outperformed approved CD20 mAbs rituximab, ofatumumab and obinutuzumab.

[E_L]

the threshold for complement activation by DuoHexaBody-CD37 might be lower, which could result in enhanced anti-tumor efficacy in clinical settings. This could be of specific interest for patients who no longer respond to CD20 mAb treatment regimens,

[E_L]

[it was also] shown to efficiently engage with FcγRs in mediating ADCC and ADCP, indicating the mechanism of action of DuoHexaBody-CD37 is multifaceted.

[E_L]

induced significant inhibition of tumor growth